

Amendments to the Specification:

Please amend the paragraph beginning at page 1, line 1, as follows:

CROSS REFERENCE TO RELATED APPLICATIONS

“This is a continuation of pending U.S. Patent Application Serial No. 10/323,433, filed on December 12, 2002; which is a division of U.S. Patent Application Serial No. 09/777,086 filed February 5, 2001; which is a continuation of U.S. Serial No. ~~07/329,900~~09/329,900, filed June 10, 1999, now U.S. Patent No. ~~6,394,317~~6,211,246 B1

Please amend the paragraph beginning at p. 2, line 24, as follows:

The nonsteroidal anti-inflammatory drugs, commonly referred to as ~~NSAISDs~~ NSAIDs, for use in the present invention are well known in the art. They may be selected from propionic acid derivatives, acetic acid derivatives, fenamic acid derivatives, and biphenylcarboxylic acid derivatives. Accordingly, the term NSAID as used herein is understood to mean any non-narcotic analgesic nonsteroidal anti-inflammatory compound, including pharmaceutically acceptable salts thereof which fall within the classes of compounds set forth above. The acceptable salts include sodium, potassium, arginine, lysine, and the like.

Please amend the paragraph beginning at p. 3, line 15, as follows:

The pharmaceutically acceptable amines include primary, secondary and tertiary amines. Suitable pharmaceutically acceptable amines include pseudoephedrine, phenylpropanolamine, dextromethorphan, chlorpheniramine, diphenhydramine, loratadine, fexofenadine, ~~and~~ citirazine, famotidine, ranitidine, cimetidine and their pharmaceutically acceptable salts.

Please amend the paragraph beginning at p. 4, line 7, as follows:

The NSAID will be dissolved or suspended, but preferably suspended, whereas the amine will be substantially dissolved in the liquid medium. As used herein, suspensions are understood to be a system in which small particles are more or less uniformly dispersed in a liquid medium. The suspensions will employ suitable

suspending and dispersing agents that are well known in the art, see for example US Pat. No. ~~5,375,659~~5,374,659 the contents of which are hereby incorporated by reference. Examples of such suspending materials include, but are not limited to, polycarbohydrates such as cellulose derivatives, starch and starch derivatives, xanthan gum, carageenan, locust bean gum, and the like, wetting agents such as sodium laurel sulfate and alkyl polyoxyethylene sulfates; sulfonates such as quaternary ammonium compounds; nonionic materials such as polyoxyethylene fatty alcohol ethers, sorbitan fatty esters and polyoxyethylene sorbitan fatty acid esters. A preferred system as disclosed in US Pat. No. 5,374,659, is comprised of xanthan gum, pregelatinized starch and polyoxyethylene monooleate. Further agents are set forth in Remington's Pharmaceutical Sciences, 15th Edition, Osal and Hoover Editors, 1975.